Joanna Socha1,2, Ewa Wasilewska-Teśluk3,4, Rafal Stando5, Lukasz Kuncman6, Lucyna Kepka1. 1. Department of Radiotherapy, Military Institute of Medicine, Warsaw, Poland. 2. Department of Radiotherapy, Regional Oncology Centre, Czestochowa, Poland. 3. Independent Public Health Care Facility of the Ministry of the Interior and Warmian & Mazurian Oncology Centre, Olsztyn, Poland. 4. Department of Oncology, Faculty of Medicine, University of Warmia & Mazury, Olsztyn, Poland. 5. Department of Radiotherapy, Holy Cross Cancer Center, Kielce, Poland. 6. Department of Radiotherapy, Medical University of Lodz, Lodz, Poland.
Abstract
OBJECTIVES: In our previous prospective trial on accelerated hypofractionated concomitant radiochemotherapy (AHRT-CHT) for non-small-cell lung cancer (NSCLC), the incidence of grade ≥3 acute esophageal toxicity (AET) was similar to that reported for conventionally fractionated concomitant radiochemotherapy (CFRT-CHT), but its duration was prolonged. Thus, we aimed to compare the duration of grade ≥3 AET between AHRT-CHT and CFRT-CHT. METHODS: Clinical data of 76 NSCLC patients treated with CFRT-CHT (60-66 Gy/2 Gy) during 2015-2020 were retrospectively compared with the data of 92 patients treated with AHRT-CHT (58.8 Gy/2.8 Gy) in the prospective trial. The maximum grade of AET, incidence, and duration of grade ≥3 AET were the end points. Univariate and multivariate analyses were applied to correlate clinical and treatment variables with these end points. RESULTS: Neither the maximum grade of AET (p = 0.71), nor the incidence of grade ≥3 AET (p = 0.87) differed between the two groups. The number of CHT cycles delivered (2 vs 1, p = 0.005) and higher esophagus mean BED (p = 0.009) were significant predictors for a higher maximum grade of AET; older age was a significant predictor for higher incidence of grade ≥3 AET (p = 0.03). The median duration of grade ≥3 AET in AHRT-CHT and CFRT-CHT group was 30 days (range 5-150) vs 7 days (range 3-20), respectively, p = 0.0005. In multivariate analysis, only the AHRT-CHT schedule (p=0.003) was a significant predictor for a longer duration of grade ≥3 AET. CONCLUSION: Despite similar incidence of grade ≥3 AET, its duration is significantly prolonged in NSCLC patients treated with AHRT-CHT compared to CFRT-CHT. ADVANCES IN KNOWLEDGE: Reporting only the rate of grade ≥3 AET in clinical trials may underestimate the real extent of the esophageal toxicity; its duration should also be routinely reported.
OBJECTIVES: In our previous prospective trial on accelerated hypofractionated concomitant radiochemotherapy (AHRT-CHT) for non-small-cell lung cancer (NSCLC), the incidence of grade ≥3 acute esophageal toxicity (AET) was similar to that reported for conventionally fractionated concomitant radiochemotherapy (CFRT-CHT), but its duration was prolonged. Thus, we aimed to compare the duration of grade ≥3 AET between AHRT-CHT and CFRT-CHT. METHODS: Clinical data of 76 NSCLC patients treated with CFRT-CHT (60-66 Gy/2 Gy) during 2015-2020 were retrospectively compared with the data of 92 patients treated with AHRT-CHT (58.8 Gy/2.8 Gy) in the prospective trial. The maximum grade of AET, incidence, and duration of grade ≥3 AET were the end points. Univariate and multivariate analyses were applied to correlate clinical and treatment variables with these end points. RESULTS: Neither the maximum grade of AET (p = 0.71), nor the incidence of grade ≥3 AET (p = 0.87) differed between the two groups. The number of CHT cycles delivered (2 vs 1, p = 0.005) and higher esophagus mean BED (p = 0.009) were significant predictors for a higher maximum grade of AET; older age was a significant predictor for higher incidence of grade ≥3 AET (p = 0.03). The median duration of grade ≥3 AET in AHRT-CHT and CFRT-CHT group was 30 days (range 5-150) vs 7 days (range 3-20), respectively, p = 0.0005. In multivariate analysis, only the AHRT-CHT schedule (p=0.003) was a significant predictor for a longer duration of grade ≥3 AET. CONCLUSION: Despite similar incidence of grade ≥3 AET, its duration is significantly prolonged in NSCLC patients treated with AHRT-CHT compared to CFRT-CHT. ADVANCES IN KNOWLEDGE: Reporting only the rate of grade ≥3 AET in clinical trials may underestimate the real extent of the esophageal toxicity; its duration should also be routinely reported.
Authors: Maria Werner-Wasik; Ellen Yorke; Joseph Deasy; Jiho Nam; Lawrence B Marks Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Sung-Ja Ahn; Daniel Kahn; Sumin Zhou; Xiaoli Yu; Donna Hollis; Timothy D Shafman; Lawrence B Marks Journal: Int J Radiat Oncol Biol Phys Date: 2005-02-01 Impact factor: 7.038
Authors: A Aupérin; C Le Péchoux; J P Pignon; C Koning; B Jeremic; G Clamon; L Einhorn; D Ball; M G Trovo; H J M Groen; J A Bonner; T Le Chevalier; R Arriagada Journal: Ann Oncol Date: 2006-03 Impact factor: 32.976
Authors: David A Palma; Suresh Senan; Cary Oberije; Jose Belderbos; Núria Rodríguez de Dios; Jeffrey D Bradley; R Bryan Barriger; Marta Moreno-Jiménez; Tae Hyun Kim; Sara Ramella; Sarah Everitt; Ramesh Rengan; Lawrence B Marks; Kim De Ruyck; Andrew Warner; George Rodrigues Journal: Int J Radiat Oncol Biol Phys Date: 2013-09-10 Impact factor: 7.038
Authors: Margriet Kwint; Wilma Uyterlinde; Jasper Nijkamp; Chun Chen; Josien de Bois; Jan-Jakob Sonke; Michel van den Heuvel; Joost Knegjens; Marcel van Herk; José Belderbos Journal: Int J Radiat Oncol Biol Phys Date: 2012-05-05 Impact factor: 7.038
Authors: Johanna Ramroth; David J Cutter; Sarah C Darby; Geoff S Higgins; Paul McGale; Mike Partridge; Carolyn W Taylor Journal: Int J Radiat Oncol Biol Phys Date: 2016-07-25 Impact factor: 7.038
Authors: Omar S Din; Susan V Harden; Emma Hudson; Nazia Mohammed; Laura S Pemberton; Jason F Lester; Debashis Biswas; Lavinia Magee; Aisha Tufail; Ross Carruthers; Ghazia Sheikh; David Gilligan; Matthew Q F Hatton Journal: Radiother Oncol Date: 2013-10-03 Impact factor: 6.280